Download Sample
Add to CartDiabetic Assays Market
By Method;
ELISA, Point Of Care Testing, Enzymatic Assay, Colorimetric Assay and OthersBy Product Type;
Instruments, Testing Kits and ReagentBy Disease Type;
Type 1 Diabetes, Type 2 Diabetes and Gestational DiabetesBy End Users;
Hospitals, Homecare, Specialty Clinics and OthersBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031)Diabetic Assays Market Overview
Diabetic Assays Market (USD Million)
Diabetic Assays Market was valued at USD 2,487.94 million in the year 2024. The size of this market is expected to increase to USD 3,340.64 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.3%.
Diabetic Assays Market
*Market size in USD million
CAGR 4.3 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 4.3 % |
| Market Size (2024) | USD 2,487.94 Million |
| Market Size (2031) | USD 3,340.64 Million |
| Market Concentration | High |
| Report Pages | 310 |
Major Players
- InSphero AG
- Abbott Laboratories
- American Laboratory Products Company (ALPCO),
- Beckmann Coulter Inc
- Bio RAD laboratories Inc
- Ortho clinical diagnostics Inc
- F. Hoffmann-la Roche Ltd
- Siemens AG
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Diabetic Assays Market
Fragmented - Highly competitive market without dominant players
The Diabetic Assays Market is witnessing accelerated growth due to the global surge in diabetes cases and increased emphasis on early diagnosis. With nearly 45% of diabetic patients requiring routine monitoring, the demand for accurate and reliable assay tools is expanding rapidly. These assays are essential in measuring biomarkers such as insulin, C-peptide, and HbA1c, which play a critical role in diabetes management and therapeutic decisions.
Technological Advancements Enhance Diagnostic Accuracy
The integration of automated platforms and multiplex assay technologies is significantly improving the precision and speed of diabetic testing. Advanced immunoassay formats and biosensor-based solutions now contribute to nearly 38% of diagnostic assay usage in clinical settings. These innovations allow for high-throughput screening, enhancing diagnostic workflows and reducing patient turnaround time.
Regulatory Support and Clinical Research Momentum
Supportive regulatory frameworks and intensified research in diabetes-related biomarkers are boosting product innovation across the market. Around 60% of clinical trials focusing on diabetes therapies incorporate diagnostic assays as part of their inclusion criteria. This interdependence highlights the role of assays in accelerating therapeutic validation and regulatory approvals.
Personalized Medicine Bolstering Assay Customization
The advancement of personalized medicine is reshaping the development of diabetic assays tailored to individual metabolic profiles. With nearly 49% of diabetes management protocols integrating personalized biomarker panels, there is a growing need for flexible and specific assay formats. This trend supports precision healthcare and optimizes treatment outcomes for diverse patient populations.
Diabetic Assays Market Key Takeaways
-
The global diabetic assays market is growing steadily, powered by the rising prevalence of diabetes and the need for accurate diagnostic and monitoring tools.
-
Advances in assay technology—such as point-of-care testing and automated platforms—are improving speed, sensitivity and ease of use in clinical and home settings.
-
Routine screening and monitoring efforts (for markers such as HbA1c, glucose and autoantibodies) are expanding in emerging regions as access to diagnostics improves.
-
North America remains a dominant region due to mature healthcare infrastructure and high diabetes awareness, while Asia-Pacific is the fastest growing region driven by large populations and increasing healthcare access.
-
The shift toward home-based testing and digital integration of diagnostics is creating opportunities for kits and remote monitoring solutions tailored to patient self-management.
-
Despite positive prospects, barriers such as high cost of advanced assays, regulatory hurdles, and limited reimbursement in certain markets may slow adoption.
-
Companies that focus on high-precision assays, user-friendly formats and broad distribution via both clinical labs and home-care channels are best positioned to succeed.
Diabetic Assays Market Recent Developments
-
In September 2022, Nanolive launched the LIVE Cell Death Assay, an automated solution for profiling cell health, death, apoptosis, and necrosis. The tool advances real-time cellular research and biomedical applications.
-
In March 2022, Biovica announced plans to establish a CLIA lab in San Diego, California. Following clearance, the facility will provide DiviTumTKa analysis to support Biovica’s customers across the United States.
Diabetic Assays Market Segment Analysis
In this report, the Diabetic Assays Market has been segmented by Method, Product Type, Disease Type, End Users and Geography.
Diabetic Assays Market, Segmentation by Method
Segmentation by Method categorizes diagnostic approaches such as immunoassays, enzymatic techniques and rapid point-of-care tests, each with unique clinical and commercial value propositions.
From a market research perspective, vendors balance accuracy, turnaround time and cost to position offerings across clinical labs, hospitals and homecare channels.
Key strategic priorities include partnerships with diagnostics labs, investments in automation and reducing time-to-result to increase adoption and enable scalable screening programs.
ELISA
ELISA (enzyme-linked immunosorbent assay) remains a cornerstone method for high-throughput, lab-based diabetic biomarker testing, valued for its analytical robustness.
Manufacturers focus on automation, kit standardization and reagent quality to reduce variability, support large-volume diagnostics and meet stringent laboratory accreditation requirements.
Strategic alliances with clinical laboratories and OEM platforms drive distribution scale and position ELISA as a reliable option for centralized testing workflows.
Point Of Care Testing
Point Of Care Testing (POCT) delivers rapid results near the patient, supporting urgent decision-making and decentralized screening in clinics and homecare settings.
POCT adoption is propelled by growing demand for immediate glycemic control data, simplified user interfaces and connectivity to electronic health records and telehealth platforms.
Vendors compete on usability, regulatory approvals and consumable economics to expand footprint in primary care and remote monitoring programs.
Enzymatic Assay
Enzymatic Assay methods are widely used for accurate quantification of glucose and related metabolites in clinical and research settings.
Providers invest in reagent stability, assay linearity and integration with automated analyzers to improve throughput and lower per-test costs.
Enzymatic techniques are often positioned as cost-effective workhorses for routine laboratory testing and mass screening initiatives.
Colorimetric Assay
Colorimetric Assay approaches offer simple visual or instrument-read outputs suitable for both point-of-care devices and lower-complexity labs.
Market focus centers on improving sensitivity, developing standardized readout devices and ensuring consistent reagent performance under varied storage and field conditions.
Colorimetric solutions are attractive in resource-constrained settings where affordability and ease-of-use are primary drivers.
Others
Others includes emerging and niche assay formats such as biosensor-based methods and multiplexed panels that complement mainstream approaches.
Innovation in this bucket often targets faster analytics, miniaturization and integration with mobile health platforms to capture new use-cases and patient-centric monitoring.
Future outlook centers on validation, regulatory clearance and commercialization partnerships to move novel assays from lab prototypes to clinical adoption.
Diabetic Assays Market, Segmentation by Product Type
Segmentation by Product Type differentiates core hardware, consumables and integrated systems that together form the diagnostic value chain.
Market strategies emphasize bundled offerings—combining instruments with validated testing kits and reagents—to lock in consumable revenue and simplify buyer procurement.
Technological advancements and supply-chain partnerships are crucial to ensure reagent consistency, instrument uptime and scalable deployment across settings.
Instruments
Instruments comprise analyzers, POCT devices and automated platforms that perform diabetic assays at scale or at the bedside.
Vendors prioritize reliability, connectivity, ease of maintenance and service agreements to minimize downtime and support clinical adoption in hospitals and centralized labs.
Product roadmaps often include integration with laboratory information systems (LIS) and remote diagnostics to enable proactive maintenance and performance optimization.
Testing Kits
Testing Kits are packaged consumables optimized for specific assay methods and intended for use with designated instruments or manual workflows.
Manufacturers focus on lot-to-lot consistency, shelf life and regulatory compliance to build trust with clinical customers and to secure long-term contracts with laboratories and distributors.
Kits are central to commercial models because they drive recurring revenue and influence channel relationships across territories.
Reagent
Reagent products underpin assay performance and are often bundled with kits or supplied independently to labs and POCT operators.
Quality control, cold-chain logistics and dependable supply are critical challenges that vendors mitigate through local manufacturing partnerships and robust distribution networks.
Investment in reagent formulation and stabilization technologies is a strategic priority to extend shelf life and expand reach into emerging markets.
Diabetic Assays Market, Segmentation by Disease Type
Segmentation by Disease Type allocates assay demand across Type 1, Type 2 and Gestational Diabetes, reflecting differing clinical pathways, screening needs and monitoring frequencies.
Market participants design diagnostic and monitoring solutions aligned to each disease’s epidemiology, patient management patterns and evidence-based treatment algorithms.
Public health screening initiatives and rising prevalence trends are primary drivers encouraging expanded testing infrastructure and chronic care monitoring programs.
Type 1 Diabetes
Type 1 Diabetes requires continuous monitoring and sensitive diagnostics for autoantibodies and glycemic control, especially in pediatric and young adult populations.
Assay strategies prioritize high analytical sensitivity, pediatric-friendly sampling options and integration with insulin delivery systems and decision-support tools.
Partnerships with endocrinology centers and pediatric networks help accelerate clinical validation and adoption of specialized diagnostic panels.
Type 2 Diabetes
Type 2 Diabetes represents the largest share of diagnostic demand due to population prevalence, screening programs and chronic disease management requirements.
Vendors concentrate on scalable, cost-effective assays for routine screening, HbA1c monitoring and comorbidity risk stratification to support primary care workflows.
Strategies include collaboration with public health initiatives and payers to expand screening coverage and improve early detection rates.
Gestational Diabetes
Gestational Diabetes necessitates targeted screening protocols during pregnancy, with emphasis on timely detection to reduce maternal and neonatal complications.
Diagnostic approaches balance sensitivity with convenience, promoting POCT and streamlined lab assays that fit prenatal care timelines and clinic workflows.
Outreach through obstetric networks and integration with prenatal screening programs supports focused growth in this segment.
Diabetic Assays Market, Segmentation by End Users
Segmentation by End Users highlights where assays are performed—hospitals, homecare, specialty clinics and other settings—each with distinct procurement and workflow needs.
Market expansion depends on channel strategies, training, reimbursement frameworks and device/regulatory fit for each end-user category.
Vendors optimize product form-factors, service offerings and distribution partnerships to meet the operational constraints and clinical expectations of each user group.
Hospitals
Hospitals represent high-volume users that demand integrated analyzers, validated kits and rigorous quality systems to support inpatient monitoring and acute care needs.
Procurement decisions are influenced by total cost of ownership, service contracts and interoperability with hospital IT systems to ensure streamlined workflows.
Hospitals often prefer enterprise agreements and turnkey installations that include training and long-term technical support to reduce operational risk.
Homecare
Homecare adoption is driven by the shift to decentralized chronic disease management and the need for patient-friendly devices with remote monitoring capabilities.
Manufacturers emphasize usability, connectivity to telehealth platforms and consumable convenience to enable adherence and real-world data capture.
Reimbursement models and partnerships with home health agencies are important levers to scale home-based testing programs.
Specialty Clinics
Specialty Clinics such as endocrinology and diabetes care centers demand specialized assays, rapid turnaround and integration with clinical decision support systems.
These clinics value advanced testing capabilities, staff training and access to multi-analyte panels to support individualized treatment plans and care coordination.
Collaborations with clinical networks and reference labs help vendors deliver bundled services that meet high-touch clinical requirements.
Others
Others captures community labs, diagnostic chains and occupational health settings where convenience, cost and throughput drive purchasing choices.
These channels often rely on distributor partnerships and regional service agreements to maintain supply continuity and technical support.
Market strategies in this bucket include regional sales expansion, localized training and flexible commercial models tailored to smaller operators.
Diabetic Assays Market, Segmentation by Geography
In this report, the Diabetic Assays Market has been segmented by Geography into five regions: North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
North America
North America is a mature market with high adoption of advanced assays, strong reimbursement frameworks and concentrated clinical research activity.
Vendors emphasize regulatory approvals, payer engagement and partnerships with major hospital systems to capture commercial volume and pilot innovation projects.
The region's demand for integrated POCT solutions and automated lab analyzers makes it a strategic priority for product launches and service expansion.
Europe
Europe demonstrates steady adoption driven by preventive health initiatives, well-established clinical laboratories and cross-border standardization efforts.
Market strategies focus on compliance with regional regulatory requirements, localization of reagents and collaborations with national healthcare programs to support screening campaigns.
Sustainability and supply-chain resilience are increasing challenges that shape procurement and vendor selection across European markets.
Asia Pacific
Asia Pacific is a high-growth region fueled by rising diabetes prevalence, expanding healthcare access and investments in diagnostic infrastructure.
Vendors pursue local manufacturing, distribution partnerships and price-competitive product lines to address diverse market segments from urban hospitals to rural clinics.
Opportunities include scaling POCT for community screening and integrating assays into public health initiatives to improve early detection rates.
Middle East & Africa
Middle East & Africa sees selective adoption concentrated in urban centers and specialized healthcare projects, often supported by government modernization programs.
Commercial activity is driven by large hospital projects, international partnerships and demand for turnkey diagnostic solutions with reliable service support.
Market entry typically requires local distributor networks, training programs and tailored commercial terms to overcome logistical and regulatory challenges.
Latin America
Latin America is expanding adoption through public health screening, private clinic modernization and growing awareness of chronic disease management.
Vendors focus on building regional distributor relationships, offering cost-effective reagent supply and training to scale laboratory capacity and point-of-care testing.
Key success factors include addressing price sensitivity, ensuring reagent availability and partnering with local health authorities for screening programs.
Diabetic Assays Market Forces
This report provides an in depth analysis of various factors that impact the dynamics of Diabetic Assays Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers:
- Rising Prevalence of Diabetes
- Technological Advancements in Assay Development
-
Increasing Awareness and Screening Programs: The surge in awareness regarding the significance of early detection and effective management of diabetes is driving the demand for diabetic assays globally. With mounting efforts from healthcare organizations and governments to spread awareness, there has been a noticeable shift towards proactive screening programs. These initiatives aim to reach high-risk populations and encourage regular testing for diabetes, facilitating early intervention and better disease management. Consequently, the growing emphasis on preventive healthcare practices is fueling the demand for diagnostic assays tailored to detect and monitor diabetes.
Healthcare organizations and governmental bodies are increasingly implementing screening programs to address the rising burden of diabetes. These programs are designed to target populations at risk, including individuals with a family history of diabetes, those with obesity, and individuals with sedentary lifestyles. By promoting regular screening and providing accessible testing options, these initiatives play a crucial role in early detection, enabling timely intervention and improved patient outcomes. As a result, the implementation of such programs contributes significantly to the expansion of the market for diabetic assays.
Efforts to enhance accessibility and promote regular screening among high-risk populations are pivotal in driving market expansion for diagnostic assays in diabetes management. By fostering a culture of proactive healthcare and early disease detection, these initiatives not only empower individuals to take charge of their health but also create a conducive environment for the adoption of diagnostic assays. As awareness continues to grow and screening programs become more widespread, the demand for diabetic assays is expected to rise, further driving market expansion and improving diabetes care globally.
Restraints:
- Cost Constraints and Reimbursement Issues
- Complex Regulatory Landscape
-
Competition from Alternative Testing Methods: Alternative testing methods, including continuous glucose monitoring (CGM) devices and non-invasive glucose monitoring technologies, present formidable competition to traditional diagnostic assays in the diabetes management landscape. These innovative approaches offer distinct advantages such as real-time monitoring and enhanced convenience for patients. Continuous glucose monitoring devices, for instance, provide continuous and dynamic glucose measurements, offering valuable insights into glucose trends and patterns over time. Similarly, non-invasive glucose monitoring technologies eliminate the need for finger pricks, offering a pain-free and non-disruptive method of glucose monitoring, which appeals to patients seeking greater comfort and convenience in managing their diabetes.
The rise of alternative testing methods poses a significant challenge to the market share of conventional diabetic assays by disrupting the status quo of glucose monitoring. Patients increasingly gravitate towards these alternative technologies due to their ability to provide real-time data and reduce the burden associated with traditional monitoring methods. The convenience offered by continuous glucose monitoring devices and non-invasive monitoring technologies makes them attractive alternatives for patients seeking more seamless and less intrusive methods of glucose monitoring, thereby posing a direct challenge to the adoption of traditional diagnostic assays.
Despite the competition posed by alternative testing methods, traditional diagnostic assays maintain their relevance and importance in the diabetes management landscape. While continuous glucose monitoring devices and non-invasive monitoring technologies offer unique benefits, traditional diagnostic assays remain integral for comprehensive diabetes care. These assays provide accurate and reliable measurements of blood glucose levels and serve as essential tools for diagnosing diabetes, monitoring treatment effectiveness, and guiding therapeutic decisions. As such, while alternative testing methods may capture a portion of the market, traditional diagnostic assays continue to play a vital role in diabetes management, especially in clinical settings where precise measurements are paramount.
Opportunities:
- Expansion in Emerging Markets
- Focus on Point-of-Care Testing
-
Advancements in Personalized Medicine: Advancements in personalized medicine are revolutionizing the landscape of diabetes management, offering tailored solutions through precision diagnostics. These advancements pave the way for the development of diabetic assays that are customized based on individual patient profiles and genetic markers. By integrating molecular and genetic testing technologies into diagnostic assays, healthcare providers can obtain a deeper understanding of each patient's unique physiological characteristics and genetic predispositions. This personalized approach enables more accurate diagnosis, risk stratification, and treatment planning, ultimately enhancing the efficacy and value of diabetic assays in healthcare settings.
The integration of molecular and genetic testing technologies into diagnostic assays represents a significant leap forward in diabetes care. By leveraging these advanced tools, healthcare providers can obtain comprehensive insights into the underlying mechanisms of diabetes and its progression. This allows for more precise diagnosis of the disease and enables proactive risk stratification, identifying individuals who may be at higher risk of developing diabetes-related complications. Additionally, the ability to tailor treatment approaches based on genetic markers and individual patient profiles enhances the effectiveness of diabetes management strategies, leading to improved patient outcomes and quality of life.
Incorporating personalized medicine principles into diabetic assays not only improves clinical decision-making but also enhances patient engagement and satisfaction. By offering individualized care plans that are tailored to each patient's unique needs and genetic makeup, healthcare providers can empower patients to take a more active role in managing their diabetes. This personalized approach fosters a deeper sense of trust and collaboration between patients and healthcare providers, ultimately leading to more successful treatment outcomes and better long-term management of diabetes.
Diabetic Assays Market Competitive Landscape Analysis
Diabetic Assays Market is characterized by increasing competition among established players and emerging innovators, with over 65% of the market share concentrated among leading firms. Companies are actively leveraging strategies like collaboration, merger, and partnerships to maintain competitive positioning. Innovation remains central, with rising focus on technological advancements driving measurable growth across diagnostics.
Market Structure and Concentration
The competitive field shows a moderately consolidated structure where top companies secure nearly 55% share. Market leaders emphasize diversified strategies to strengthen portfolios through regional expansion. Mid-tier players adopt collaboration models to gain traction, while new entrants focus on cost-effective innovation to penetrate competitive segments efficiently.
Brand and Channel Strategies
Strong brands hold about 60% influence in purchase decisions, supported by robust distribution and awareness campaigns. Companies invest in digital engagement and strategic partnerships to expand accessibility. Localized channel approaches enhance regional trust, while mergers and alliances with diagnostic centers improve market penetration and brand loyalty across diverse healthcare ecosystems.
Innovation Drivers and Technological Advancements
Nearly 70% of industry players prioritize research pipelines to introduce novel diabetic assays. Advanced biomarker testing and automation platforms reflect rapid technological advancements. Firms invest in integrated solutions that align with digital health ecosystems, ensuring growth through cutting-edge platforms and fostering competitive differentiation in this evolving diagnostic segment.
Regional Momentum and Expansion
North America and Europe collectively account for close to 58% of market presence, driven by strong collaboration between manufacturers and healthcare providers. Asia-Pacific reflects the fastest regional expansion, with about 45% of emerging players targeting these geographies. Regional strategies emphasize cost efficiency and innovation, reshaping competitive benchmarks across international markets.
Future Outlook
The market anticipates sustained growth, with 62% of companies expected to prioritize mergers and partnerships to enhance global footprints. Emerging strategies include expanding assay portfolios and leveraging digital integration for efficiency. Competitive momentum will be defined by technological advancements and regional expansion, ensuring a robust landscape with a strong trajectory toward innovation-driven competitiveness.
Key players in Diabetic Assays Market include:
- Abbvie, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.
- Merck KGaA
- Abbott Laboratories
- Siemens
- Bio-Rad Laboratories, Inc.
- BIOMÉRIEUX
- DiaSorin S.p.A.
- DRG Instruments GmbH
- BAG Diagnostics GmbH
- QuidelOrtho Corporation
- PTS Diagnostics
- Diazyme Laboratories
In this report, the profile of each market player provides following information:
- Market Share Analysis
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Method
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Type
- Market Snapshot, By End Users
- Market Snapshot, By Region
- Diabetic Assays Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers:
- Rising Prevalence of Diabetes
- Technological Advancements in Assay Development
- Increasing Awareness and Screening Programs
- Restraints:
- Cost Constraints and Reimbursement Issues
- Complex Regulatory Landscape
- Competition from Alternative Testing Methods
- Opportunities:
- Expansion in Emerging Markets
- Focus on Point-of-Care Testing
- Advancements in Personalized Medicine
- Drivers:
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Diabetic Assays Market, By Method, 2021 - 2031 (USD Million)
- ELISA
- Point Of Care Testing
- Enzymatic Assay
- Colorimetric Assay
- Others
- Diabetic Assays Market, By Product Type, 2021 - 2031 (USD Million)
- Instruments
- Testing Kits
- Reagent
- Diabetic Assays Market, By Disease Type, 2021 - 2031 (USD Million)
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Diabetic Assays Market, By End Users, 2021 - 2031 (USD Million)
- Hospitals
- Homecare
- Specialty Clinics
- Others
- Diabetic Assays Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Diabetic Assays Market, By Method, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbvie, Inc.
- Novartis AG
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.
- Merck KGaA
- Abbott Laboratories
- Siemens
- Bio-Rad Laboratories, Inc.
- BIOMÉRIEUX
- DiaSorin S.p.A.
- DRG Instruments GmbH
- BAG Diagnostics GmbH
- QuidelOrtho Corporation
- PTS Diagnostics
- Diazyme Laboratories
- Company Profiles
- Analyst Views
- Future Outlook of the Market